Romain Altwegg
A5084003535- Inflammatory Bowel Disease
- Microscopic Colitis
- Immunodeficiency and Autoimmune Disorders
- Autoimmune and Inflammatory Disorders
- Eosinophilic Esophagitis
- Diagnosis and treatment of tuberculosis
- Diverticular Disease and Complications
- Liver Diseases and Immunity
- Systemic Lupus Erythematosus Research
- Biosimilars and Bioanalytical Methods
- Chronic Lymphocytic Leukemia Research
- Gastric Cancer Management and Outcomes
- Tuberculosis Research and Epidemiology
- Pharmaceutical studies and practices
- Celiac Disease Research and Management
- Gallbladder and Bile Duct Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Pregnancy and Medication Impact
- Autoimmune and Inflammatory Disorders Research
- Clostridium difficile and Clostridium perfringens research
- Gastrointestinal motility and disorders
- Gastrointestinal Tumor Research and Treatment
- Gastroesophageal reflux and treatments
- Colorectal Cancer Surgical Treatments
- Esophageal and GI Pathology
Centre Hospitalier Universitaire de Montpellier
2016-2025
Université de Montpellier
2016-2025
Hôpital Saint Eloi
2016-2025
Institute for Regenerative Medicine & Biotherapy
2022
Groupe d'Étude Thérapeutique des Affections Inflammatoires du Tube Digestif
2019
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2013
Hospital Clínic de Barcelona
2013
Goethe University Frankfurt
2013
University Hospital Frankfurt
2013
CEA Valduc
2012
The efficacy of anti-tumour necrosis factors (anti-TNFs) in patients with Crohn's disease (CD) and symptomatic small bowel stricture (SSBS) is controversial. aim this study was to estimate the adalimumab these identify predicting success.We performed a multicentre, prospective, observational cohort CD SSBS. included underwent magnetic resonance enterography at baseline subsequently received adalimumab. primary endpoint success week 24, defined as continuation without prohibited treatment...
The QUASAR Phase 2b Induction Study evaluated the efficacy and safety of guselkumab, an interleukin-23p19 subunit antagonist, in patients with moderately to severely active ulcerative colitis (UC) prior inadequate response and/or intolerance corticosteroids, immunosuppressants, advanced therapy.
Summary Background We recently showed that vedolizumab is effective in patients with Crohn's disease (CD) and ulcerative colitis (UC) prior anti‐TNF failure a multicentre compassionate early‐access programme before marketing authorisation was granted to vedolizumab. Aims To assess effectiveness safety of at week 54 UC CD. Methods Between June December 2014, 173 121 were treated induction therapy. Among those 294 patients, 272 completed the period evaluated 14 visit (161 CD 111 UC). Disease...
The effectiveness of vedolizumab as a treatment for extraintestinal manifestations (EIM) is questionable due to its gut-specificity.To assess EIM in patients with inflammatory bowel disease (IBD) large real-life experience cohort.Between June and December 2014, 173 Crohn's 121 ulcerative colitis were treated vedolizumab. Patients followed until week 54. activity was assessed at weeks 0, 6, 14, 22, 30 54 by using 3-step scale: complete remission, partial response no response.At baseline, 49...
Summary Background Phase III trials have demonstrated the efficacy and safety of ustekinumab in moderate‐to‐severe ulcerative colitis (UC), but few real‐world data are currently available. Aim To assess short‐term effectiveness patients with UC. Methods From January to September 2019, all UC treated 20 French GETAID centres were retrospectively included. The primary outcome was steroid‐free clinical remission (partial Mayo Clinic score ≤2) at weeks 12‐16 without a rectal bleeding subscore...
Summary Background The prevalence of inflammatory bowel diseases (IBD) is high in women childbearing age. Achieving clinical remission from conception to delivery using current medications a major issue IBD. Aims To assess maternal and neonatal complications management vedolizumab or ustekinumab) pregnant with IBD receiving these agents. Methods We performed retrospective cohort study among GETAID centres including who received ustekinumab during pregnancy within the 2 months before compared...
Abstract Background The approved maintenance regimens for ustekinumab in Crohn’s disease [CD] are 90 mg every 8 or 12 weeks. Some patients will respond partially to experience a secondary loss of response. It remains poorly known if these may benefit from shortening the interval between injections. Methods All with active CD, as defined by Harvey–Bradshaw score ≥ 4 and one objective sign inflammation [C-reactive protein > 5 mg/L and/or faecal calprotectin 250 µg/g radiological...
Summary Background Up to 25% of patients with ulcerative colitis (UC) will require hospitalization for severe flare. In hospitalised flare, who previously experienced multiple drug failures, including steroids and anti‐TNF agents, new quick‐acting medical options are needed. Tofacitinib is effective in refractory UC has a rapid onset action. Aim To evaluate effectiveness safety tofacitinib as rescue therapy Methods We conducted an observational multicentre study both retrospective...
Bevacizumab-a humanized monoclonal antibody-has been widely used to treat patients with hereditary hemorrhagic telangiectasia (HHT), but no randomized trial has yet conducted.This study is a double-blind multicenter phase 2 1:1 active-treatment-to-placebo ratio. We included over the age of 18 confirmed diagnosis and need for at least four red blood cell (RBC) units transfused in 3 months before enrollment. Bevacizumab was administered dose 5 mg/kg every 14 days total six injections. The...
Both vedolizumab and ustekinumab can be considered for the treatment of ulcerative colitis [UC], but head-to-head trials are lacking. We aimed to compare effectiveness after anti-tumour necrosis factor [anti-TNF] failure in UC patients. In this multicentre study, we included consecutive adult patients with UC, partial Mayo score >2 prior anti-TNF exposure, treated or between January 2019 August 2022. Comparisons were performed using propensity analyses [inverse probability weighting]. Among...
to describe the characteristics of incident cases tuberculosis [TB] despite negative TB screening tests, in patients with inflammatory bowel disease [IBD] undergoing anti-TNF treatment, and identify risk factors involved. A retrospective descriptive study was conducted at GETAID centers on all IBD treatment who developed even though their initial test results were negative. The following data collected using a standardized anonymous questionnaire: IBD, evolution, methods results, time before...
Whether vedolizumab may be effective as a treatment for primary sclerosing cholangitis [PSC] in patients with inflammatory bowel disease [IBD] remains controversial.We performed retrospective observational study of consecutive IBD and PSC, treated at least 30 weeks 22 centres GETAID from January 2015 to June 2016. The outcomes included decrease the serum alkaline phosphatase [ALP] concentration 50% baseline Week or 54, change any liver enzymes concentrations, an assessment efficacy safety...
Summary Background Cohort studies have described the short‐term effectiveness and safety of vedolizumab in treating patients with Crohn's disease (CD) ulcerative colitis (UC), but data beyond 1 year are lacking. Aim To assess after 162 weeks UC CD. Methods Between June December 2014, 294 including 173 CD 121 were treated induction therapy. Among them, 149 continued to be week 54 (78 71 UC). Disease activity was assessed using Harvey‐Bradshaw Index for partial Mayo Clinic score UC. The...